Pliant Therapeutics Inc. Insider Trading

PLRX

Last 12 months

Insiders sold 164K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market

−164K

0 buys · 4 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

None

in the last two years

Get an email when PLRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jan 20	Keith Lamont Cummings Chief Financial Officer	Sold10b5-1 plan	24,002	$1.28	31K	7.5%	Form 4
Jan 20	Lily Cheung Chief Human Resource Officer	Sold10b5-1 plan	7,534	$1.28	10K	14%	Form 4
Jan 20	Bernard Coulie President and CEO	Sold10b5-1 plan	89,375	$1.28	114K	8.9%	Form 4
Jan 20	Minnie Kuo Chief Operating Officer	Sold10b5-1 plan	6,917	$1.28	9K	15%	Form 4
Jan 17, 2025 – Jan 22, 2025	Mike Ouimette General Counsel & Corp. Sec'y	Sold10b5-1 plan 2 parts	23,500	$11.11 average	261K	25%	Form 4
Jan 17, 2025	Bernard Coulie President and CEO	Sold10b5-1 plan	52,419	$11.20	587K	5.9%	Form 4
Jan 17, 2025	Keith Lamont Cummings Chief Financial Officer	Sold10b5-1 plan	20,148	$11.20	226K	7.1%	Form 4
Jan 17, 2025	Hans Hull Chief Business Officer	Sold10b5-1 plan	15,936	$11.20	178K	6.6%	Form 4
Jan 17, 2025	Eric Lefebvre Chief Medical Officer	Sold10b5-1 plan	18,478	$11.20	207K	8.7%	Form 4
Jan 17, 2025	Lily Cheung Chief Human Resource Officer	Sold10b5-1 plan	3,740	$11.20	42K	13%	Form 4

Jan 2010b5-1 plan
Keith Lamont Cummings
Chief Financial Officer · sold 24,002 at $1.28
31K
7.5% of stake
Jan 2010b5-1 plan
Lily Cheung
Chief Human Resource Officer · sold 7,534 at $1.28
10K
14% of stake
Jan 2010b5-1 plan
Bernard Coulie
President and CEO · sold 89,375 at $1.28
114K
8.9% of stake
Jan 2010b5-1 plan
Minnie Kuo
Chief Operating Officer · sold 6,917 at $1.28
9K
15% of stake
Jan 17, 2025 – Jan 22, 202510b5-1 plan
Mike Ouimette
General Counsel & Corp. Sec'y · sold 23,500 at avg $11.11
261K
25% of stake
Jan 17, 202510b5-1 plan
Bernard Coulie
President and CEO · sold 52,419 at $11.20
587K
5.9% of stake
Jan 17, 202510b5-1 plan
Keith Lamont Cummings
Chief Financial Officer · sold 20,148 at $11.20
226K
7.1% of stake
Jan 17, 202510b5-1 plan
Hans Hull
Chief Business Officer · sold 15,936 at $11.20
178K
6.6% of stake
Jan 17, 202510b5-1 plan
Eric Lefebvre
Chief Medical Officer · sold 18,478 at $11.20
207K
8.7% of stake
Jan 17, 202510b5-1 plan
Lily Cheung
Chief Human Resource Officer · sold 3,740 at $11.20
42K
13% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PLRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PLRX

CompareIntrinsic value

AARDAardvark Therapeutics, Inc.

$1.36-5.56%10

ORMPOramed Pharmaceuticals Inc.

$4.11-2.84%35

NTHINeonC Technologies Holdings

$3.26+4.49%10

SLNSilence Therapeutics plc

$19.75-0.25%10

SEPNSepterna, Inc.

$43.97-2.79%48

AXSMAxsome Therapeutics, Inc.

$144.01+0.39%10

NKTXNkarta Inc.

$1.56-6.02%10

TNXPTonix Pharmaceuticals Holding Corp

$5.09-3.60%40

Held by ETFs

PLRX is in 1 US ETF. The largest of them, with PLRX's weight in each:

Vanguard Health Care ETFVHT0.00%of the fund

Spot a number that looks wrong? Check it in PLRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PLRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.